Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.

The New England journal of medicine - 30 Apr 2026

Heymach John V, Yamamoto Noboru, Girard Nicolas, Ruiter Gerrina, Smit Egbert F, Planchard David, Nadal Ernest, Wu Yi-Long, Zugazagoitia Jon, Tu Hai-Yan, Baik Christina S, Yoh Kiyotaka, Soo Ross A, Zhao Yanqiu, Sabari Joshua K, Wermke Martin, Scheffler Matthias, Ahn Myung-Ju, Fernamberg Kristie, Schroeter Lukas, Sadrolhefazi Behbood, Thamer Claus, Eigenbrod-Giese Sabina, Popat Sanjay

Abstract excerpt

BACKGROUND: Until recently, no first-line targeted treatment options were available for patients with human epidermal growth factor receptor 2 (HER2)-mutant non-small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible tyrosine kinase inhibitor that selectively inhibits HER2 while sparing wild-type epidermal growth factor receptor (EGFR), thereby minimizing associated toxic effects. METHODS: We...

Topics

Join the communities discussing this publication.

Acrylamides
Brain Neoplasms
Carcinoma, Non-Small-Cell Lung
Erb-b2 Receptor Tyrosine Kinases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Progression-Free Survival

Tyrosine Kinase Inhibitors

Source

Identifiers

PMID: 41985129
DOI: 10.1056/NEJMoa2516969

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

First-Line Zongertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.PMID 41985129Read ↗

Zongertinib in Previously Treated HER2 -Mutant Non–Small-Cell Lung CancerSemantic proximity Read ↗

Zongertinib: First Approval.Semantic proximity Read ↗

Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report.Semantic proximity Read ↗

The development of Zongertinib for HER2-mutant NSCLCSemantic proximity Read ↗

Evaluating zongertinib in the treatment of patients with HER2-mutant non-small cell lung cancer.Semantic proximity Read ↗

The role of zongertinib, a highly selective tyrosine kinase inhibitor, in targeting HER2-mutant NSCLC: a bench-to-bedside review.Semantic proximity Read ↗

Evaluation of zongertinib for the treatment of metastatic non-squamous non-small cell lung cancer with HER2 TKD activating mutation.Semantic proximity Read ↗

Recent Advances in the Development and Clinical Use of HER2 Inhibitors in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Sevabertinib in Advanced HER2-Mutant Non-Small-Cell Lung Cancer.Semantic proximity Read ↗

First-line zorifertinib for EGFR-mutant non-small cell lung cancer with central nervous system metastases: The phase 3 EVEREST trial.Semantic proximity Read ↗

Nazartinib for treatment-naive EGFR-mutant non-small cell lung cancer: Results of a phase 2, single-arm, open-label study.Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitor for the treatment of non-small cell lung cancer in the past 30 years (1997-2026).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.